A mitochondria-targeted tetrapeptide (Elamipretide) that binds cardiolipin on the inner mitochondrial membrane to restore cristae architecture and bioenergetic efficiency.
Sourced from Ascension Peptides. Verified purity, third-party tested. COA included.
Buy Now →SS-31, known by its clinical development name elamipretide, is a synthetically manufactured mitochondria-targeted tetrapeptide with the amino acid sequence D-Arg-Dmt-Lys-Phe-NH2 — where Dmt denotes 2′,6′-dimethyltyrosine, a non-standard amino acid modification that contributes to the molecule’s cell membrane permeability and antioxidant properties. It was developed by scientists at Weill Cornell Medicine (the Szeto-Schiller peptide series, from which the “SS” designation derives) and has been advanced clinically by Stealth BioTherapeutics, a Boston-based biopharmaceutical company that focused its development program on rare mitochondrial diseases.
Unlike the vast majority of therapeutic peptides, which exert their effects at cell surface receptors or in the extracellular space, SS-31 is specifically designed to penetrate cell membranes and localize to the inner mitochondrial membrane (IMM), where its primary molecular target — cardiolipin, a unique phospholipid critical to mitochondrial function — resides. This intramitochondrial targeting is the defining pharmacological feature that distinguishes SS-31 from all conventional receptor-targeted therapeutics and from other cellular antioxidants like coenzyme Q10 that do not achieve the same selective IMM localization.
The clinical development of elamipretide has progressed furthest in Barth syndrome — a rare X-linked genetic disorder caused by mutations in the tafazzin gene (TAZ) that impair cardiolipin remodeling, leading to skeletal and cardiac myopathy. The TAZPOWER trial, a Phase 3 randomized controlled study conducted by Stealth BioTherapeutics, evaluated elamipretide’s effects on skeletal muscle function in Barth syndrome patients and is the most rigorous clinical evaluation of the compound to date. Beyond Barth syndrome, SS-31 has been studied in heart failure with preserved ejection fraction (HFpEF), primary mitochondrial myopathy (PMM), and aging-related frailty — applications that reflect the breadth of conditions in which mitochondrial dysfunction is now recognized as a contributing pathophysiological mechanism.
As of 2026, elamipretide has not received FDA approval for any indication. Its development trajectory and the broader scientific interest in targeting cardiolipin and mitochondrial bioenergetics represent a frontier in pharmaceutical science with potentially wide-ranging implications. For mechanism comparisons with other mitochondria-targeted compounds, visit the Peptide Database or consult the AI Coach.
Cardiolipin (CL) is a structurally unique phospholipid found almost exclusively in the inner mitochondrial membrane, where it constitutes approximately 15–20% of the total IMM lipid content. Its distinctive bisphosphatidyl-glycerol structure with four acyl chains gives it exceptional capacity to interact with membrane proteins, particularly the electron transport chain (ETC) complexes and ATP synthase. Cardiolipin functions as a structural scaffold for ETC supercomplexes — the organized assemblies of Complexes I, III, and IV that channel electrons efficiently and reduce electron leak — and as a direct cofactor for cytochrome c electron transfer activity. In disease states including genetic cardiolipin deficiency (Barth syndrome), oxidative stress-related cardiolipin peroxidation, and aging-associated mitochondrial dysfunction, cardiolipin integrity is compromised, disrupting supercomplex organization and reducing bioenergetic efficiency. SS-31’s therapeutic mechanism begins with its selective accumulation at the IMM, driven by electrostatic interaction between its positively charged residues (D-Arg and Lys) and the negative charge of cardiolipin’s phosphate head groups, combined with the hydrophobic interactions of the Dmt and Phe residues with the lipid bilayer. This results in concentrations of SS-31 at the IMM that are estimated to be several hundred-fold higher than cytosolic concentrations, achieving local therapeutic concentrations at the precise molecular location where cardiolipin damage and ETC dysfunction occur. Once localized, SS-31’s aromatic Dmt residue intercalates between cardiolipin acyl chains, stabilizing cardiolipin against peroxidation by physically shielding the susceptible polyunsaturated fatty acid chains from oxidant attack while also exerting direct electron-scavenging activity through its phenolic hydroxyl group.
Cytochrome c is a small heme-containing protein that shuttles electrons between Complex III (ubiquinol-cytochrome c reductase) and Complex IV (cytochrome c oxidase) in the electron transport chain. Its activity depends critically on the physical state of the cardiolipin that anchors it near the IMM surface — when cardiolipin is peroxidized or depleted, cytochrome c becomes loosely associated with the membrane, its electron-carrying function becomes less efficient, and its potential to participate in apoptotic signaling (by being released into the cytoplasm to activate caspase-9) increases. SS-31’s cardiolipin-protective action directly addresses this vulnerability: by preserving the structural integrity of cardiolipin’s interaction domain, SS-31 maintains cytochrome c in its optimal electron-transfer-competent configuration, tethered appropriately to the IMM in close proximity to Complex III and IV. This optimization of cytochrome c’s coupling between Complexes III and IV is mechanistically important because electron transfer between these complexes is a critical juncture for both efficient ATP production and electron leak. When electron handoff between Complex III and cytochrome c is incomplete or delayed due to disrupted cardiolipin-protein interactions, electrons can leak from Complex III to molecular oxygen, generating superoxide — the precursor to most biologically damaging ROS species. By ensuring efficient electron transfer through the cytochrome c junction, SS-31 reduces the electron dwell time at Complex III and minimizes superoxide formation, producing a quantitative reduction in mitochondrial ROS output that propagates to reduced oxidative damage across the cell.
Mitochondrial cristae — the elaborate infoldings of the inner mitochondrial membrane that dramatically expand its surface area — are not merely structural features but are dynamic functional domains that concentrate respiratory chain components and create the proton gradient microenvironments required for efficient ATP synthesis. Cristae morphology is regulated by a network of proteins including the MICOS complex (mitochondrial contact site and cristae organizing system), OPA1 (which oligomerizes to form cristae junctions), and critically, cardiolipin — which is highly enriched at cristae junctions and is required for MICOS complex stability and OPA1 oligomerization. When cardiolipin is depleted or peroxidized, cristae architecture deteriorates: junctions widen, cristae sheets fragment, and the concentrated respiratory chain environment is lost, with corresponding decreases in respiratory efficiency. Transmission electron microscopy studies in cardiolipin-deficient cells and aged mitochondria consistently show disorganized, diminished cristae. SS-31 treatment has been shown in multiple model systems to preserve or restore cristae architecture: in tafazzin-knockout cell models of Barth syndrome, SS-31 treatment improved cristae morphology assessed ultrastructurally, correlating with functional improvements in ETC activity. In aged cardiac and skeletal muscle, SS-31 treatment partially restored cristae density and organization to patterns more consistent with younger animals. The preservation of cristae structure by SS-31 likely represents an upstream structural mechanism that produces broad downstream functional consequences across all ETC complexes — making cristae preservation a potentially important mediator of SS-31’s therapeutic effects across its diverse range of applications from genetic disease to aging.
The TAZPOWER trial (Trial of Elamipretide in Patients with Barth Syndrome) was a double-blind, randomized, placebo-controlled, 12-week Phase 3 trial conducted across multiple sites in North America and Europe, enrolling 12 patients (consistent with the extreme rarity of Barth syndrome) in a crossover design. The primary endpoint was the distance walked in six minutes (6-minute walk test, 6MWT) — a well-validated functional outcome measure in neuromuscular and cardiac conditions. In the elamipretide arm, patients showed an average improvement of 95 meters in 6MWT distance, which did not achieve nominal statistical significance given the very small sample size in this ultra-rare disease (p=0.118). Secondary endpoints, however, revealed consistent signals: improvements in patient-reported outcome measures of fatigue and physical capacity, favorable trends in cardiac structure assessments including reduced left ventricular end-systolic volume and improved global longitudinal strain, and improvements in platelet cardiolipin profiles — a molecular biomarker of systemic cardiolipin remodeling consistent with the drug’s proposed mechanism. The small sample size inherent to Barth syndrome’s rarity (estimated prevalence of approximately 1 in 300,000–400,000 males) means that TAZPOWER was almost certainly underpowered to detect a primary endpoint effect even if one exists. Stealth BioTherapeutics conducted open-label extension studies that showed sustained functional improvements with continued elamipretide treatment over 168 weeks (approximately three years), providing longer-term data that supports the functional benefit signals observed acutely.
HFpEF accounts for approximately half of all heart failure cases and represents one of the most therapeutically challenging conditions in cardiovascular medicine — a syndrome where the heart’s pumping fraction is normal or near-normal but diastolic stiffness prevents adequate ventricular filling, producing symptoms of breathlessness, fatigue, and exercise intolerance. Mitochondrial dysfunction has been increasingly recognized as a central feature of the HFpEF myocardium: cardiomyocytes in HFpEF patients exhibit reduced oxidative phosphorylation capacity, elevated ROS, diminished ATP/ADP ratios under stress, and altered fatty acid oxidation — all consistent with impaired ETC function. This metabolic characterization makes HFpEF theoretically well-suited to mitochondria-targeted therapy with SS-31. A Phase 2 clinical trial (EFFORT-HFpEF) evaluated intravenous elamipretide in patients with stable HFpEF. The trial showed that elamipretide treatment improved left atrial volume index (a marker of chronic filling pressure elevation), peak oxygen consumption (VO2 peak) during cardiopulmonary exercise testing, and patient-reported quality of life scores. Mechanistically, the cardiac improvement aligns with the compound’s ability to restore mitochondrial energetics in metabolically stressed cardiomyocytes that are not contractile-apparatus dysfunctional but rather energetically limited in their capacity to relax and fill. These Phase 2 findings generated considerable interest, though the larger Phase 3 trials needed to confirm these findings and support regulatory approval have faced the development challenges that ultimately led Stealth BioTherapeutics to restructure its development program.
Primary mitochondrial myopathies (PMM) are a heterogeneous group of genetic disorders caused by mutations in mitochondrial DNA or nuclear genes encoding mitochondrial proteins, collectively resulting in impaired ETC function and consequent skeletal and/or cardiac muscle weakness. The MMPOWER trials evaluated elamipretide in PMM patients with the primary endpoint of improvement in 6MWT distance. MMPOWER-3, a 24-week randomized controlled trial, enrolled 218 patients across multiple PMM subtypes and demonstrated that elamipretide treatment produced clinically meaningful improvements in 6MWT distance (mean improvement of approximately 21 meters versus 8 meters with placebo) and in patient-reported fatigue scores. While the trial’s primary endpoint did not reach statistical significance at the prespecified threshold due to greater-than-expected placebo response (a common challenge in functional outcome trials in rare neuromuscular diseases), the consistent directional benefit across functional and patient-reported endpoints supported the biological plausibility of the treatment approach. The open-label extension of MMPOWER-3 showed sustained improvement in patients who continued elamipretide treatment, and the functional trajectories differed meaningfully between patients who received continuous treatment versus those who switched from placebo — a crossover signal that supports genuine therapeutic activity. PMM represents an important proof-of-concept indication for SS-31 because the diseases are mechanistically directly linked to ETC dysfunction — the precise molecular dysfunction SS-31 addresses — providing a more direct mechanistic-clinical link than the pleiotropic pathologies of HFpEF or aging.
Perhaps the most expansive research frontier for SS-31 is its application to aging itself — specifically the hypothesis that mitochondrial dysfunction is a primary driver of the physical frailty, sarcopenia, and multi-organ functional decline that characterize normal aging. Mitochondrial aging is characterized by progressive accumulation of mtDNA damage, increased electron leak and ROS production, cardiolipin peroxidation causing ETC inefficiency, and reduced mitochondrial biogenesis signal amplitude. Skeletal muscle in particular shows dramatic age-related decline in mitochondrial respiration capacity that correlates with the reduced VO2 max, muscle weakness, and exercise intolerance that define physical frailty. Preclinical studies in aged mice have shown that SS-31 treatment improves skeletal muscle mitochondrial respiration, increases physical performance on treadmill and grip strength testing, and reduces markers of oxidative stress — findings replicated across multiple independent research laboratories. A Phase 2 human aging trial (the LIFE-Extension trial conducted in collaboration with the NIA’s TRIAD consortium) evaluated elamipretide in older adults with physical frailty, measuring mitochondrial function via 31P-MRS (phosphorus magnetic resonance spectroscopy), physical performance battery scores, and patient-reported outcomes. Early reported results showed improvements in mitochondrial ATP production kinetics and trends toward improved physical performance, supporting the translational validity of the preclinical aging findings. These aging applications position SS-31 at the intersection of mitochondrial medicine and the emerging geroscience paradigm — the framework that aging itself, rather than individual age-related diseases, is a tractable therapeutic target.
A substantial preclinical literature supports SS-31’s potential as an organ-protective agent in ischemia-reperfusion (I/R) injury contexts — the tissue damage that occurs when blood flow is restored to an ischemic organ after a period of insufficient perfusion. I/R injury is a major contributor to organ damage in cardiac surgery, organ transplantation, myocardial infarction, and stroke. Mitochondrial dysfunction — particularly the opening of the mitochondrial permeability transition pore (mPTP) triggered by calcium overload and ROS surge upon reperfusion — is the central mediator of I/R cell death. SS-31 treatment in rodent I/R models has consistently shown reductions in infarct size, preserved organ function, and histological evidence of reduced cell death when administered before or at the time of reperfusion. In cardiac I/R models, SS-31 reduced mitochondrial swelling, mPTP opening, and cardiomyocyte death, with corresponding improvements in left ventricular recovery following ischemia. In renal I/R models relevant to contrast-induced nephropathy and renal transplantation, SS-31 reduced tubular cell apoptosis and preserved GFR. While these preclinical findings have not yet been translated to approved clinical organ protection applications, the mechanistic coherence — mPTP protection through cardiolipin and ETC stabilization during the high-ROS reperfusion window — provides a strong rationale for clinical evaluation in perioperative cardioprotection settings.
Elamipretide has been administered via two routes in clinical trials: subcutaneous injection and intravenous infusion. In the Barth syndrome TAZPOWER trial, subcutaneous injection of 40 mg elamipretide once daily was the treatment protocol — representing the most extensively evaluated chronic dosing regimen in a human clinical trial. This 40 mg daily subcutaneous dose has become the reference clinical dose for elamipretide’s development program. In acute and perioperative settings (including Phase 2 HFpEF studies), shorter-course intravenous infusion protocols have been used, typically with 0.05–0.25 mg/kg administered as a 4-hour intravenous infusion on a defined course schedule. Plasma pharmacokinetics of subcutaneous elamipretide show rapid absorption with peak concentrations within 1–2 hours of injection and a half-life that supports once-daily dosing. The compound distributes rapidly to highly metabolically active tissues, consistent with its mitochondria-targeted mechanism — heart, skeletal muscle, and kidney show the highest tissue concentrations relative to blood in preclinical distribution studies. For research applications and dosing context, our peptide calculators provide reference frameworks.
The clinical trial subcutaneous injection protocol for elamipretide used a standardized preparation of the peptide in an aqueous formulation administered via small-volume subcutaneous injection. Injection sites in TAZPOWER and MMPOWER trials included the abdomen, upper arm, and thigh, with rotation across sites recommended for daily injections. Given the once-daily dosing schedule, the practical injection burden is comparable to other therapeutic peptides including liraglutide and semaglutide. In the Barth syndrome patient population — which includes pediatric and adolescent patients with the rare genetic condition — the subcutaneous route was feasible and well-tolerated, with injection site reactions representing the most common local adverse event. The formulation details of the clinical drug product — preservatives, pH, osmolality — are proprietary to Stealth BioTherapeutics’ pharmaceutical development. Any research use of SS-31 outside of clinical trials must use research-grade material of verified composition and purity from qualified suppliers, administered under appropriate medical oversight.
In published preclinical research, SS-31 has been administered across a wide range of doses and schedules reflecting the diversity of rodent model applications. Acute cardioprotection studies have used bolus doses of 1–3 mg/kg administered intraperitoneally at the time of reperfusion. Chronic aging and frailty studies have used daily subcutaneous injections of 0.5–3 mg/kg for periods of weeks to months. Renal I/R protection protocols have used single or short-course intraperitoneal injection at doses of 1–5 mg/kg. The translation of rodent preclinical doses to human clinical doses involves complex allometric scaling considerations, and the 40 mg daily clinical dose represents the outcome of formal pharmacokinetic/pharmacodynamic modeling and dose-ranging studies rather than direct linear allometric conversion from rodent data. For researchers studying SS-31 in preclinical settings and seeking comparative context, the Peptide Database contains summary tables of doses used across different model systems in published literature.
As elamipretide’s development continues, there is scientific interest in alternative delivery modalities beyond daily subcutaneous injection — particularly for long-term use in aging and frailty applications where daily injections represent a practical adherence burden. Sustained-release formulations, topical ophthalmic delivery for retinal applications (the eye being a highly mitochondria-dependent organ where local delivery is feasible), and intranasal delivery for CNS applications are areas of preclinical investigation. For HFpEF, where intermittent intravenous infusion was used in Phase 2, defining the optimal intermittent dosing interval to maintain cardiac mitochondrial functional improvement is an important unanswered pharmacodynamic question. The AI Coach can provide the most current information on elamipretide’s clinical and preclinical development status as new studies are published.
The safety profile of elamipretide across the Barth syndrome, PMM, and HFpEF clinical trial programs is characterized by good overall tolerability, with injection site reactions representing the most commonly reported adverse events in the subcutaneous administration trials. Injection site erythema, induration, pruritus, and mild pain were reported in a substantial proportion of patients in TAZPOWER and MMPOWER studies, consistent with the daily injection schedule and the relatively large injection volume of the 40 mg dose. While these local reactions were generally mild to moderate in severity and did not typically lead to discontinuation, they represent a quality-of-life consideration for patients who may use the compound long-term. The reactions are consistent with subcutaneous injection of a cationic peptide in a high-concentration formulation rather than being compound-specific toxicity signals. Systemic adverse events reported in clinical trials have been comparable to placebo in frequency and severity, with no specific organ-directed toxicity signals identified in the trial programs to date. Fatigue, headache, and nausea were among the most common systemic events but occurred at rates not meaningfully different from placebo-treated participants.
Given SS-31’s primary mechanism of action in the heart and its development in populations with pre-existing cardiac disease (Barth syndrome patients have cardiomyopathy; HFpEF patients have heart failure), careful cardiovascular safety monitoring was incorporated into all clinical trial programs. No evidence of proarrhythmic effects, worsening heart function, or cardiotoxicity has been identified in clinical trial populations. In fact, cardiac function trends — particularly in Barth syndrome patients — have been directionally favorable on structural and functional cardiac assessments. Renal function monitoring has similarly not revealed nephrotoxic signals, which is reassuring given the compound’s mitochondrial targeting mechanism and the abundance of mitochondria in renal tubular epithelium. Hematological assessments — including complete blood counts and platelet function evaluation, which is particularly relevant in Barth syndrome where thrombocytopenia is a known disease feature — have not shown elamipretide-attributable cytopenias. The overall cardiovascular and organ safety profile across the clinical program has been consistent with what would be expected from a compound acting at the mitochondrial level without receptor-targeted pharmacological effects on cardiovascular physiology.
Long-term safety data for elamipretide beyond the MMPOWER-3 and TAZPOWER open-label extension studies (covering up to 168 weeks) are limited, reflecting the relatively early stage of the compound’s clinical development. The open-label extension data have not revealed delayed or cumulative toxicity signals over this observation period, though the very small numbers of Barth syndrome patients available for long-term study limit the statistical power to detect rare adverse events. Stealth BioTherapeutics encountered significant commercial and financial challenges in 2021-2022 that led to restructuring of its development program, affecting the pace at which elamipretide’s clinical development has advanced. These business environment factors, rather than safety or efficacy concerns, have been the primary constraints on elamipretide’s development trajectory. Research interest in the compound and its mechanism remains high in the academic mitochondrial medicine community, with multiple investigator-initiated studies ongoing through NIA, NIH, and independent research institutions that are generating new safety and efficacy data independent of the commercial development pathway. For the most current information on ongoing elamipretide studies, ClinicalTrials.gov and the AI Coach are the best sources of updated trial status.
Most antioxidant supplements — vitamin C, vitamin E, resveratrol, CoQ10 — work by scavenging ROS after they have been generated, either throughout the cell or in specific compartments. SS-31 is fundamentally different: it reduces ROS production at the source by improving the efficiency of electron transfer through the mitochondrial electron transport chain, preventing the electron leak that generates superoxide in the first place. Additionally, because SS-31 targets the inner mitochondrial membrane specifically, it achieves highly localized therapeutic concentrations at the exact site of ROS production without flooding the rest of the cell with an antioxidant that would interfere with normal physiological redox signaling. This precision mitochondrial targeting is what sets SS-31 apart from conventional antioxidant strategies that have generally failed in clinical trials.
Barth syndrome is a rare X-linked genetic disorder caused by mutations in the tafazzin gene (TAZ), which encodes an enzyme required for the remodeling of cardiolipin’s acyl chain composition to its mature, predominantly tetralinoleoyl form. Without functional tafazzin, cardiolipin composition is abnormal and total cardiolipin levels are reduced, directly impairing ETC supercomplex organization and mitochondrial bioenergetics. Clinically, Barth syndrome manifests as dilated cardiomyopathy, skeletal myopathy, growth retardation, neutropenia, and exercise intolerance. Because SS-31’s mechanism directly addresses cardiolipin dysfunction — it binds to and protects cardiolipin, preserving ETC function — Barth syndrome represents the most direct mechanistic match between the drug’s mechanism and a disease’s molecular pathology. This is why Barth syndrome was selected as the lead indication for SS-31’s Phase 3 development.
The TAZPOWER trial showed clinically meaningful but not statistically significant improvement in 6-minute walk test distance (95 meters versus placebo, p=0.118) in 12 Barth syndrome patients, with positive secondary endpoints including patient-reported fatigue and cardiac functional parameters. The trial was not powered to achieve statistical significance given the rarity of the disease. Elamipretide has not received FDA approval. Stealth BioTherapeutics subsequently pursued a regulatory pathway based on the totality of evidence including open-label extension data, but the company’s financial difficulties have affected the regulatory submission timeline. As of 2026, elamipretide remains investigational in the US.
Preclinical research in aged rodents consistently shows SS-31 improves multiple aging-related outcomes: skeletal muscle mitochondrial respiration, physical performance, cardiac function, and markers of oxidative stress. Early Phase 2 human data in older adults with physical frailty show improvements in mitochondrial ATP production kinetics measured noninvasively. These findings are mechanistically coherent — mitochondrial dysfunction and cardiolipin peroxidation are well-documented features of normal aging — and represent a legitimate research rationale. However, no clinical trial has yet demonstrated that SS-31 slows aging-related decline in a human population over a clinically meaningful timeframe, and the compound is not approved for any aging indication. The NIA’s engagement in SS-31 aging research through the TRIAD consortium reflects the scientific community’s interest in pursuing these questions rigorously.
Cardiolipin is a specialized phospholipid found almost exclusively in the inner mitochondrial membrane. It serves multiple critical roles: it physically scaffolds the electron transport chain complexes into high-efficiency supercomplexes, it acts as a proton-trapping cofactor that helps sustain the electrochemical gradient driving ATP synthase, it tethers cytochrome c for efficient electron shuttling between Complexes III and IV, and it supports the structural integrity of the cristae folds that concentrate respiratory machinery. When cardiolipin is peroxidized (damaged by ROS), depleted by genetic defects (as in Barth syndrome), or qualitatively altered by disease states, ETC efficiency falls, ROS production rises, and mitochondrial structural organization deteriorates — a cascade that drives pathology across numerous diseases. Protecting cardiolipin is the central therapeutic action of SS-31.
SS-31 (D-Arg-Dmt-Lys-Phe-NH2) can be synthesized by peptide chemistry suppliers and is available for in vitro and preclinical research use through qualified research peptide suppliers. However, pharmaceutical-grade elamipretide for human administration is not commercially available outside of authorized clinical trials; Stealth BioTherapeutics retains proprietary rights to the clinical-grade formulation. Research-grade SS-31 from peptide suppliers has variable purity and characterization and is intended for laboratory research only — not for human administration. Given that the clinical trial evidence base uses the proprietary pharmaceutical formulation, results from research-grade material may not directly translate to clinical outcomes. Any human research application must use appropriately characterized and manufactured material under IND authorization.
MitoQ and SkQ1 are mitochondria-targeted antioxidants that use a triphenylphosphonium (TPP) cation to drive selective accumulation in the mitochondrial matrix, where they act as ubiquinol-based radical scavengers. SS-31 is distinct in several important ways: it targets the inner mitochondrial membrane (not the matrix), its primary action is improving ETC electron transfer efficiency and protecting cardiolipin structure rather than scavenging ROS in the matrix, and it does not use the TPP delivery vehicle, which has its own off-target membrane depolarization properties at high concentrations. SS-31 also directly engages cardiolipin as a structural therapeutic target, a mechanism not shared by MitoQ or SkQ1. The clinical development of SS-31 is substantially more advanced than MitoQ or SkQ1, with SS-31 having reached Phase 3 in rare disease and Phase 2 in HFpEF where the other compounds have primarily remained in preclinical or Phase 1 stages.
In both HFrEF (reduced ejection fraction) and HFpEF, cardiomyocyte mitochondria undergo progressive dysfunction: substrate preference shifts from efficient fatty acid oxidation to less energetically favorable glucose oxidation, ETC complex activities decline, mitochondrial ROS production increases, and ATP production capacity falls below the heart’s energetic demand particularly during exercise or stress. In HFpEF specifically, the metabolic signature of the myocardium is one of bioenergetic insufficiency in cardiomyocytes that are structurally intact but energetically impaired — which is why the ejection fraction is preserved (the pumping force remains adequate at rest) but diastolic filling is impaired (relaxation requires energy and is disproportionately sensitive to bioenergetic deficiency). SS-31 addresses this by restoring ETC efficiency through cardiolipin protection and cytochrome c electron transfer optimization, improving the cardiomyocyte’s capacity to generate the ATP required for both active myosin cross-bridge cycling and the SERCA pump activity that drives calcium reuptake and myocardial relaxation.
Disclaimer: This information is for research and educational purposes only. It is not medical advice. Consult a qualified healthcare professional before using any peptide.